EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Translating Lipoprotein Genetics Into New Therapies

Robert A Hegele iD

Circulation Research · 05.06.2026 · 138 (12)

DOI: 10.1161/circresaha.126.328828 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Circulation Research, erschienen am 05.06.2026. Verfasst von Robert A Hegele. Beteiligte Einrichtung: Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Dyslipidemias, Lipoproteins, Translational Research, Biomedical. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 134 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human genetics has become the primary engine for identifying lipid-lowering drug targets and predicting therapeutic success or failure. Monogenic family studies and population-based sequencing identify individuals with lifelong loss-of-function variants in lipoprotein-regulatory genes who are simultaneously healthier and inadvertent proof-of-concept trial participants—the human knockout paradigm. This approach has driven approvals across multiple mechanistic classes targeting PCSK9 (proprotein convertase subtilisin/kexin type 9; low-density lipoprotein cholesterol lowering with demonstrated cardiovascular benefit), APOC3 (apolipoprotein C-III; olezarsen and plozasiran, both approved for triglyceride lowering in familial chylomicronemia syndrome), and ANGPTL3 (angiopoietin-like protein 3, evinacumab, approved for homozygous familial hypercholesterolemia), while Mendelian randomization prospectively identified HDL (high-density lipoprotein) cholesterol as a noncausal biomarker, predicting the failure of HDL-raising therapy in outcomes trials. RNA-based pharmacology— N -acetylgalactosamine-conjugated small interfering RNAs and antisense oligonucleotides—has emerged as a pragmatic platform for translating genetic target validation into durable, infrequently dosed therapies. Cardiovascular outcomes trials of these RNA-based agents are pending or have not yet been announced. Gene-editing approaches now extend this logic toward potentially permanent intervention. Genome-wide association studies and polygenic risk scores have expanded the landscape of candidate targets but have yet to achieve translational yield comparable to rare-variant genetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasLipoproteinsTranslational Research, BiomedicalHumansProprotein Convertase 9AnimalsAngiopoietin-Like Protein 3Apolipoprotein C-IIIOligonucleotides, Antisense

Stichwörter der Autor:innen

RNA, small interferingapolipoproteinscholesteroldyslipidemiasgenomicsoligonucleotides, antisensetriglycerides

Substanzen

Proprotein Convertase 9PCSK9 protein, humanAngiopoietin-Like Protein 3Apolipoprotein C-IIIOligonucleotides, AntisenseANGPTL3 protein, humanLipoproteinsAPOC3 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

ORCID-Profile: Robert A Hegele

Zitieren

APA

Hegele, R. A. (2026). Translating Lipoprotein Genetics Into New Therapies. Circulation Research, 138(12). https://doi.org/10.1161/circresaha.126.328828

Vancouver

Hegele RA. Translating Lipoprotein Genetics Into New Therapies. Circulation Research. 2026;138(12). doi:10.1161/circresaha.126.328828

BibTeX
@article{Hegele2026,
  author = {Hegele, Robert A},
  title = {Translating Lipoprotein Genetics Into New Therapies},
  journal = {Circulation Research},
  year = {2026},
  volume = {138},
  number = {12},
  doi = {10.1161/circresaha.126.328828}
}
Kostenlos starten →